Clinical Trials Browser

OTHER × Multiple Sclerosis × 90 days × Clear all

NCT07526493 2026-04-13

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT05819008 2026-04-01

Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries

Recruiting

350 enrolled

CNS

Brain Injuries, Traumatic, Brain Neoplasms, Epilepsy, Multiple Sclerosis, Parkinson Disease, Stroke

NCT05057676 2026-03-11

AIM

Phase NA Recruiting

400 enrolled

Post-Acute COVID-19 Syndrome, Fibromyalgia, Multiple Sclerosis

NCT07392528 2026-02-11

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Not yet recruiting

15 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica